GlassScriptPhysician profile
Mark Asef
NPI 1225561673
$2,221.11
in general payments reported to CMS, 2019-2025
19 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $210 · 2023: $793 · 2024: $712 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.86 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $835.68 | 2022-2025 | Lokelma, Farxiga |
| Aurinia Pharma U.S., INC. | $235.80 | 2023-2025 | Lupkynis |
| Ardelyx, INC. | $193.81 | 2024-2025 | Ibsrela |
| Amgen INC. | $162.82 | 2023-2024 | Parsabiv, Aranesp, Tavneos |
| Akebia Therapeutics INC | $148.19 | 2022-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $99.01 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $83.44 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $79.60 | 2023-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $77.66 | 2023-2025 | Tarpeyo |
| Apellis Pharmaceuticals, INC. | $73.56 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $53.65 | 2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.91 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $32.77 | 2024 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $21.39 | 2025 | |
| Novo Nordisk INC | $20.00 | 2025 | Rybelsus, Ozempic |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $18.65 | 2022 | |
| Vifor Pharma, INC. | $18.56 | 2024 | Veltassa |
| Lilly USA, LLC | $18.41 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $15.20 | 2025 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Asef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.